Zopiclone Market Overall Study Report 2021-2028 | Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc.

Global Zopiclone market analysis

Overview

Zopiclone is a cyclopyrrolone that belongs to the class of psychotherapeutic agents used to cure insomnia. It is sold as a tablet. It works as an amino butyric acid agonist, causing signal propagation through nerves in the brain to be blocked. As a result, zopiclone has a soothing effect on the user, which increases the sleep period.

Zopiclone has myorelaxant, anxiolytic, and anticonvulsant properties in addition to its hypnotic effect. Zopiclone is readily ingested after a single oral dosage, with a bioavailability of about 80%, and spread to salivary glands, brain tissues, breast milk, and the placenta. Zopiclone is metabolised extensively and excreted in breast milk, vomit, and saliva (about five hour excretion life.). Drugs are available from companies including Hikma Pharmaceuticals PLC, Sumitomo Dainippon Pharma Co. Ltd., Glenmark Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., and others.

To Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/3385

Drivers

Leading manufacturers are concentrating on zopiclone production, which is expected to help the global zopiclone market expand. Since the patent on the name (zopiclone) expired in 2014, several companies released generic versions of the drug. Generic has been launched in the U.S. by companies including Mylan and Dr. Reddys Laboratories. Furthermore, according to an article released in October 2018 by the non-profit organisation Best Practice Advocacy Centre New Zealand, New Zealand is the biggest consumer of prescription hypnotic medication, with zopiclone being the most often prescribed hypnotic.

The same source also revealed the following statistics to reflect the number of patients suffering from insomnia per 1,000 people in New Zealand in 2017: under 25 years old (3.2 patients), 26–35 years old (18.9 patients), 36–45 years old (30.4 patients), 46–55 years old (45.6 patients), 56–65 years old (60.7 patients), and over 65 years (86.9 patients).

In Asia Pacific, the prevalence of insomnia is smaller than in Europe and North America. As per the NCBI (National Center for Biotechnology Information), the geriatric community experiences insomnia, as well as other mental illnesses such as depression, anxiety, and post-traumatic stress disorder in 2019. Comorbid health conditions such as GERD (gastroesophageal reflux disease), restless leg syndrome, persistent pain and respiratory problems, as well as alcohol or drug dependence, may also lead to insomnia, according to the same report.

Restraints

During the forecast period, the following factors are expected to limit the global zopiclone market's growth. Manufacturers' introduction of alternate therapeutic solutions for insomnia, such as new medications and gadgets, is likely to slow the development of the zopiclone tablets sector. Cervella Cranial Electrotherapy Stimulator, a non-drug based alternative medication for anxiety, depression, and insomnia, obtained FDA approval in March 2019 from Innovative Neurological Devices LLC. Ramelteon, a new generic insomnia treatment introduced by Dr. Reddy's Laboratories in July 2019, was also approved by the US FDA. The medication belongs to the melatonin receptor agonist family, whereas zopiclone belongs to the GABA receptor agonist class.

For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/3385

Regional Analysis

Due to the high presence of key players in North America, the region is expected to maintain a leading role in the global zopiclone market over the forecast period. Furthermore, the rising prevalence of insomnia in North America and Europe is projected to boost business demand. As per PLOS One, about 27.1 percent of people in the U.S. and 37.2 percent of people in France and Italy suffer from insomnia in 2017.

The same source added that about 5% of people in China, 15.3 percent of people in Japan, and 17.3 percent of people in Singapore suffer from insomnia in the Asia Pacific region. During the forecast period, these factors are expected to fuel the Asia Pacific zopiclone market growth.

Key Players

Major companies contributing in the global zopiclone market include Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., AvKARE Inc., Macleods Pharmaceuticals Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, and Sun Pharma Pharmaceutical Industries Ltd.

To Direct Purchase this Premium Research Report – https://www.coherentmarketinsights.com/insight/buy-now/3385

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.